1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-020, NCT00689936
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 0 to 55
Sponsor: Other
Protocol IDs: 8717, NCT00673114
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: UCBT001, NCT00676806
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 11300A, NCT00683046
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPKC412D2201, NCT00782067
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 70
Sponsor: NCI, NHLBI
Protocol IDs: 606, U01 HL069294, NCT00864227
|
|
10.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MPC-2130-04-002, NCT00387153
|
|
11.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 12 to 70
Sponsor: NCI
Protocol IDs: UMN-2007LS022, UMN-2007LS022, UMN-MT2006-01, UMN-0701M00303, UMN-12559, UMN-6220-04, NCT00602693
|
|
12.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A8081001, NCT00585195
|
|
13.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1311002, SNX-5422-CLN1-002, NCT00595686
|
|
14.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 0C-07-6, NCT00630760
|
|
15.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: PR001-CLN-pro017, NCT00634504
|
|
16.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP24534-07-101, NCT00660920
|
|
17.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-2007-0595, 2007-0595, 8109, NCT00678223
|
|
18.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 265-102, NCT00679133
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 15 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLI-107-08, MSKCC IRB #07-127, NCT00684008
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2008_538, MK8669-004, NCT00730379
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SB939-2006-001, NCT00741234
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-454, NCT00743028
|
|
23.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 and over
Sponsor: Other
Protocol IDs: 2008-0384, NCT00761644
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TAK-901_101, NCT00807677
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2009_569, MK8669-037, NCT00874731
|
